
==== Front
MoleculesMoleculesmoleculesMolecules1420-3049MDPI 10.3390/molecules23113019molecules-23-03019ReviewNutritional Regulators of Bcl-xL in the Brain Park Han-A 1*Broman Katheryn 1Stumpf Allison 1Kazyak Sara 12Jonas Elizabeth A. 3Koulen Peter Academic Editor1 Department of Human Nutrition and Hospitality Management, College of Human Environmental Science, The University of Alabama, Tuscaloosa, AL 35487, USA; kabroman@crimson.ua.edu (K.B.); aastumpf@crimson.ua.edu (A.S.); srkazyak@crimson.ua.edu (S.K.)2 Department of Biological Sciences, College of Arts and Sciences, The University of Alabama, Tuscaloosa, AL 35487, USA3 Department of Internal Medicine, Section of Endocrinology, Yale University, New Haven, CT 06520, USA; elizabeth.jonas@yale.edu* Correspondence: hpark36@ches.ua.edu; Tel.: +1-205-348-8051; Fax: +1-205-348-298219 11 2018 11 2018 23 11 301910 8 2018 18 11 2018 © 2018 by the authors.2018Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).B-cell lymphoma-extra large (Bcl-xL) is an anti-apoptotic Bcl-2 protein found in the mitochondrial membrane. Bcl-xL is reported to support normal brain development and protects neurons against toxic stimulation during pathological process via its roles in regulation of mitochondrial functions. Despite promising evidence showing neuroprotective properties of Bcl-xL, commonly applied molecular approaches such as genetic manipulation may not be readily applicable for human subjects. Therefore, findings at the bench may be slow to be translated into treatments for disease. Currently, there is no FDA approved application that specifically targets Bcl-xL and treats brain-associated pathology in humans. In this review, we will discuss naturally occurring nutrients that may exhibit regulatory effects on Bcl-xL expression or activity, thus potentially providing affordable, readily-applicable, easy, and safe strategies to protect the brain.

Bcl-xLmitochondrianeuroprotectionnutrients
==== Body
1. Introduction
The Bcl-2 family of proteins are best known for their role in apoptosis by means of mitochondrial membrane permeabilization and subsequent caspase regulation. Bcl-2 proteins are structurally similar in that they all share one or more of four Bcl-2 homology (BH) domains: BH2, BH1, BH3, and/or BH4. Generally, the Bcl-2 proteins are divided into two groups, anti-apoptotic and pro-apoptotic. Anti-apoptotic proteins such as Bcl-2 and Bcl-xL contain all four homologues. Among four BH domains, the BH4 domain has been shown to be essential for the anti-apoptotic properties of Bcl-2 and Bcl-xL by its ability to inactivate pro-apoptotic effector proteins such as Bax [1,2]. Mutation on the BH4 domain reduces stability of Bcl-2 protein and interferes occupation of Bax by Bcl-2 [3]. In addition to its ability to heterodimerize pro-apoptotic Bcl-2 proteins, the BH4 domain is reported to interact with the C-terminal of inositol 1,4,5-trisphosphate receptor (IP3R) inhibiting calcium-mediated apoptosis [4]. Pro-apoptotic proteins are further classified into two groups: multidomain and BH3-only. The multidomain pro-apoptotic proteins include Bax and Bak. Once activated by BH3-only proteins, Bax and Bak promote apoptosis by transitioning from inactive monomers to oligomers, leading to the permeabilization of the mitochondrial outer membrane. Additionally, Bax and Bak can be inhibited by the anti-apoptotic members of the Bcl-2 family [5]. BH3-only proteins are unique in their pro-apoptotic mechanisms; the activator such as Bid promotes oligomerization of Bax and Bak [6,7,8], whereas the sensitizers such as PUMA and Bad sequestrate anti-apoptotic Bcl-2 proteins favoring apoptotic signaling [9].

B-cell lymphoma-extra large (Bcl-xL) is a mitochondrially localized, anti-apoptotic member of the Bcl-2 protein family. Bcl-xL has been shown to bind with pro-apoptotic Bcl-2 proteins such as Bax, Bak and Bad, thereby preventing apoptotic signaling that leads to the opening of pro-apoptotic mitochondrial ion channels [10,11,12,13]. By doing so, Bcl-xL supports cell survival by inhibiting intrinsic death pathways such as cytochrome c release and apoptosome assembly [14,15,16]. Although Bcl-xL is best known for its pro-survival role in cancer cells, additional functions of Bcl-xL in the central nervous system (CNS) have been recently reported. Bcl-xL is highly expressed in various regions of the brain including hippocampus, cortex, and hypothalamus [17,18,19], and it is abundantly found in both neurons and glia [18,20,21,22]. During prenatal development, various Bcl-2 proteins, such as Bcl-2, Bax, and Bcl-xL are expressed in the brain. However, protein levels of Bcl-xL remain high after birth through adulthood, thus Bcl-xL may be the critical player to protect the adult brain [23]. Bcl-xL enhances intracellular energy metabolism by supporting the activity of the F1Fo ATP synthase [24]. Energy conservation by actions of Bcl-xL may prevent neuronal injury caused by oxygen or glucose deficits during pathological processes of the brain. Bcl-xL is also reported to promote formation of synapses and recycling of synaptic vesicles, both of which are necessary for neuronal plasticity and recovery [25,26,27]. Bcl-xL is required for the extension and branching of neurites which is essential for both normal brain development and brain recovery after a neurotoxic event [21]. Due to its importance in brain functions, alteration of Bcl-xL activities or expression levels is highly associated with pathological processes in the brain (Table 1) [28,29].

In contrast to its protective role, Bcl-xL is also responsible for causing neuronal death during neurotoxic challenge. Bcl-xL undergoes caspase 3-dependent N-terminal cleavage forming ∆N-Bcl-xL (Figure 1) [65]. Loss of CA1 hippocampal neurons after cerebral ischemia is highly associated with the accumulation of ∆N-Bcl-xL in vivo [18,66,67]. Additionally, excitotoxicity, the major neuronal death signal during cerebral stroke caused by a surge of glutamate, leads to an abundance of ∆N-Bcl-xL in primary neurons in vitro [68]. Approaches that inactivate ∆N-Bcl-xL or prevent the accumulation of ∆N-Bcl-xL using cleavage resistant animal models, delivering pharmacological inhibitors, and applying ischemic preconditioning protect neurons by improving mitochondrial function against neurotoxic stimuli [18,66,67,68,69,70].

In addition to its role regulating the function of brain cells, Bcl-xL participates in intracellular signaling by interacting with various protein partners during physiological and pathological processes in cells [29]. Bcl-xL directly binds to the subunit of F1Fo ATP synthase [14,24]. Formation of a Bcl-xL-F1Fo ATP synthase complex prevents a proton leak through the c-subunit ring of F1Fo ATP synthase and increases intracellular ATP production [24,71]. Maintaining a functional population of neurons is energy-demanding: neurotransmission consumes a large amount of energy. Actin and tubulin polymerization during neuronal outgrowth require ATP and GTP, respectively. Therefore, Bcl-xL-dependent augmentation of neuronal energy status favors neurite outgrowth [21], synapse formation [26], and protection against ischemia-induced energy deficit [18,66]. 

Bcl-xL also directly binds to the IP3R located on the endoplasmic reticulum (ER) [72,73]. Opening of IP3R releases calcium from the ER to mitochondria regulating mitochondrial energy metabolism. Mitochondrial calcium influx controls activities of dehydrogenases such as pyruvate dehydrogenase [74,75,76], thus regulating mitochondrial NADH. Abundance of mitochondrial NADH increases availability of electrons supporting operation of the electron transport chain and synthesis of ATP. Studies have reported that calcium directly binds to F1Fo ATP synthase and regulates ATP production [77,78,79], and binding between calcium in large quantities and ATP synthase may also produce pathological mitochondrial membrane depolarization [80]. Together, the proximity between mitochondria and the ER regulates mitochondrial energy metabolism which is in turn regulated by Bcl-xL. This may further influence synaptic transmission and neuronal development. In addition, augmentation of ATP synthesis via formation of a Bcl-xL-F1Fo ATP synthase complex may influence IP3R activities. Since IP3R contains ATP binding sites and opening of the IP3R is regulated by different concentrations of ATP [81,82], Bcl-xL may also be responsible for controlling IP3R activation through enhanced production of ATP at sites closely apposed to the ER in the mitochondrial associated membrane (MAM). 

In addition to Bcl-xL and IP3R interaction, mitochondrial calcium influx may be regulated by Bcl-xL dependent voltage-dependent anion channel (VDAC) activities [83,84,85]. VDAC is expressed on the mitochondrial outer membrane, and it is reported to have multiple protein binding partners such as the adenine nucleotide translocator (ANT), hexokinase, and Bcl-2 family proteins. Formation of a multiprotein complex or oligomerization with other VDAC channels allows transport of ATP, ADP, NADH, metabolites (e.g., pyruvate, succinate), ions (e.g., Mg2+, and Ca2+), and cytochrome c [86,87]. Various groups have shown an interaction between Bcl-xL and VDAC [83,85,88,89], and formation of a Bcl-xL-VDAC complex can either enhance or inhibit activity of VDAC [90,91]. GST pulldown assay showed that VDAC 1 and 3 directly bind to both recombinant and endogenous Bcl-xL protein, and this interaction was associated with increases of mitochondrial calcium influx [83], whereas binding of the Bcl-xL BH4 domain with VDAC inhibited mitochondrial calcium uptake [85] via a reduction of channel conductance which may be associated with protection against apoptotic signaling [88].

Beclin-1, a critical player initiating autophagy [92,93,94], contains a BH3 domain. The crystal structure demonstrated a direct interaction between Beclin-1 and Bcl-xL, and occupation of Beclin-1 in the hydrophobic groove of Bcl-xL [95]. Dissociation of Bcl-xL and Beclin-1 induces autophagy in cancer cells [96], and mutation of the BH3 domain in Beclin-1 alters Bcl-xL-mediated autophagy [97] indicating regulatory roles of Bcl-xL in cell degradation. Interestingly, co-immunoprecipitation studies reveal that Bcl-xL also serves as a binding partner of PTEN-induced putative kinase 1 (PINK1), a mitochondrial serine/threonine kinase responsible for inducing mitochondrial autophagy (mitophagy) [98]. PINK1 phosphorylates ubiquitin, promotes recruitment of PARKIN and LC3, thus PINK1 facilitates formation of the autophagosome [98,99,100]. Alteration of PINK1 is highly associated with Parkinson’s disease [101,102] due to failure of mitochondrial quality control such as accumulation of impaired mitochondria. Although it is unknown how formation of a Bcl-xL-PINK1 complex directly influences mitophagy, PINK1 exhibits neuroprotective effects by phosphorylating serine 62 of Bcl-xL under apoptotic stimulation. PINK1-mediated phosphorylation of Bcl-xL inhibits N-terminal cleavage of Bcl-xL, thus preventing accumulation of neurotoxic ΔN-Bcl-xL [103].

Given these findings, Bcl-xL may be a necessary molecular player to maintain normal brain cell function, and it may be an important contributor to the delay and prevention of neurodegenerative processes [28,29]. Although it is necessary to pinpoint specific pathways of Bcl-xL-mediated neuroprotection using molecular approaches, currently reported strategies to manipulate Bcl-xL gene or protein may have limitations to translate into human subjects: Application of the pharmacological inhibitor (e.g., ABT-737) showed strong neuroprotective effects by blocking accumulation of ΔN-Bcl-xL but this drug does not cross the blood-brain barrier [18,68,104]. Overexpression of Bcl-xL improves neuronal survival [30,105] and Bcl-xL cleavage resistant animals protect the brain against ischemic injury [18], but genetic modification is still challenging to apply in human subjects. Currently, there are no FDA approved medications or treatments that specifically prevent Bcl-xL loss or promote Bcl-xL retention in human brain. In this review, we aim to introduce applicable strategies, nutritional intervention, that potentially regulate Bcl-xL protein, gene, or activity in the brain. Although limited information is available to explain a direct relationship between nutrients and Bcl-xL at the current time (Table 2), nutritional intervention may be an important extension in the field of Bcl-xL research due to its advantage in availability, low-toxicity, and cost-effectiveness. Here, we will discuss nutritional candidates that may participate in intracellular signaling pathways to delay degeneration of neurons or to promote recovery after neurotoxic insults via controlling expression of Bcl-xL.

2. Soy and Soy Isoflavones
Isoflavones are found predominantly in the legume family of flowering plants. In the human diet, soy isoflavones are often consumed in the form of soy or soy products, with the primary isoflavones being genistein, daidzein, and glycitein [128,129]. Soy isoflavones are called phytoestrogens due to chemical similarity with 17β-estradiol [130]. Studies have shown that soy isoflavones exert moderate levels of hormone-like effects or antagonize the interaction between estrogen and the estrogen receptor [131,132]. 

Soy isoflavones are reported to cross the blood-brain barrier [133]. Various research groups have reported improvement of the anti-apoptotic Bcl-2 protein profile in the brain after consumption of a soy diet or soy isoflavones in neurodegenerative models such as stroke, Alzheimer’s, and Parkinson’s disease [107,108,134,135,136]. Supplementation with soy isoflavones supports neuronal survival via enhancing Bcl-xL mRNA or protein expression in rodent brains [106,107,108,137]. Lovekamp-Swan et al. showed that rats supplemented with 600 µg/g soy isoflavones for 2 weeks prior to induction of middle carotid artery occlusion (MCAO), an experimental model to mimic focal ischemia, reduced MCAO-induced infarct size and protected brain cells from apoptotic death [107]. This group also showed that animals fed with a high soy diet had significantly enhanced mRNA and protein levels of Bcl-xL, without increasing Bcl-2 expression [107]. Interestingly, a high soy diet downregulated active caspase 3, the major contributor to the conversion of anti-apoptotic Bcl-xL to pro-apoptotic ∆N-Bcl-xL. Thus, oral supplementation of soy may prevent apoptotic pathways by preventing accumulation of pro-death ΔN-Bcl-xL and enhancing production of pro-survival Bcl-xL. Although limited information exists explaining the direct mechanisms of soy isoflavone-mediated Bcl-xL upregulation, soy isoflavone may interact with estrogen response elements (ERE) controlling Bcl-xL transcription. The bcl-x gene, BCL2L1, has been determined to contain an ERE at the 3′ untranslated region, indicating the target of transcriptional regulation via estrogen [138]. As soy isoflavones and 17β-estradiol both bind to estrogen receptor β [131,139], soy isoflavones may enhance Bcl-xL expression through transcriptional regulation by targeting EREs on BCL2L1. 

In addition, Jiang et al. orally delivered various concentrations (20, 40, and 80 mg/kg body weight) of genistein, an abundantly found isoflavone in legumes including soybeans, to rat pups for 12 days and studied the effects of genistein in isoflurane-induced neurodegeneration [137]. Isoflurane inhalation increased fluoro-jade positive degenerating neurons in the hippocampal CA1, CA3, and dentate gyrus regions whereas genistein treatment significantly protected from this neuronal loss in dose dependent manner. Animals supplemented with genistein showed upregulation of Bcl-xL and Bcl-2, and down regulation of Bad and Bax protein levels in the brain leading to improvement in cognitive behaviors [137]. This group further found that genistein treatment significantly increased AKT and phosphorylated AKT protein levels [137]. AKT, protein kinase B, is a serine/threonine kinase that is responsible for the phosphorylation of pro-apoptotic Bad and Bax [140,141,142]. The phosphorylation status of Bad and Bax influences heterodimerization with anti-apoptotic Bcl-2 proteins such as Bcl-xL [141,143]. 

Orally delivered soy isoflavones prevented loss of Bcl-xL protein in the rat brain after intraperitoneal injection of amyloid-β peptides (Aβ) indicating the therapeutic potential of soy isoflavones in the treatment of patients with Alzheimer’s disease [108]. In this study, rats were gavaged with soybean isoflavone (80 mg/kg/day) for 14 days, then Bcl-xL protein levels were quantified using brain tissue. Soybean isoflavone fed group were resistant against Aβ-mediated Bcl-xL loss. Although molecular mechanisms of soy isoflavone-mediated neuroprotection against Aβ-induced oxidative damage are unclear, upregulation of Bcl-xL protein may be beneficial to block activation of Aβ. Conversion of amyloid precursor protein (APP) to active Aβ peptides requires proteolytic cleavage by proteases such as secretases and caspases [144,145,146,147]. Since Bcl-xL binds to the apoptosome and blocks activation of down-stream caspases in the intrinsic apoptotic pathway [148,149], increasing Bcl-xL protein expression by soy isoflavone may further arrest caspase-dependent post-translational modification of APP. 

3. Ginseng and Ginsenosides
Panax ginseng has been used as a traditional medicine in Asia. Ginseng contains carbohydrates, oils, and amino acids. Most importantly, steroid derivatives of ginseng, ginsenosides (also called ginseng saponin), are reported to be the pharmaceutically functional molecule [150,151]. Antioxidant, anti-inflammatory, and anticancer effects of ginseng have been reported by various laboratories [152,153,154,155]. Moreover, neuroprotective effects of ginseng have been widely documented using both in vivo and in vitro models. Panaxadiol saponins of gisenoside Rb1 have been shown to decrease the loss of interneurons, astrocytes, and microglia in rats treated with kainic acid, an agonist of the AMPA/kainate glutamate receptor, thus preventing kainite-induced experimental seizures [156]. Further research suggests that ginsenoside Rg1 also decreased the MCAO-induced infarct volume in rat brains, indicating therapeutic effects of ginseng to prevent cerebral ischemia [157]. Interestingly, ginseng exerts neuroprotective properties in a concentration dependent manner. A low concentration of panaxatriol saponin treatment attenuated the loss of dopaminergic neurons in zebrafish whereas a high concentration caused neurotoxicity [158]. In vitro approaches using SH-SY5Y cell lines showed similar findings [159]. Ginsenoside Rd significantly increased cell viability at both 1 and 10 µM concentrations against in Parkinson’s Disease models, but it failed to do so at a higher concentration of 50 µM. At both lower concentrations, a decrease in oxidative stress and an increase in superoxide dismutase activity was recorded [159]. Therefore, it is possible that a low or a high concentration of ginsenosides may protect brain cells or facilitate death in malignant cells, respectively. 

Upregulation of Bcl-xL protein by ginseng administration has been reported in various brain-associated disease models including bacterial inflammation, cerebral ischemia, and spinal cord injury [109,110,111,112,113]. Zhang et al. has reported that ginsenoside Rb1 protects the brain against ischemic insult in a Bcl-xL dependent manner [109]. Rats underwent intravenous infusion of ginsenoside Rb1 (6 or 60 µg/µL) for 4 weeks after induction of MCAO. Ginsenoside Rb1 treated animals showed an upregulation of Bcl-xL mRNA and protein in the stroke-affected cortex which was associated with a decrease in cortical infarct size, attenuated apoptosis, and improved navigational ability. This group identified the signal transducer and activator of transcription 5 (STAT5) as being under the control of ginsenoside Rb1-mediated Bcl-xL gene regulation. STAT5 contains a DNA binding domain and acts as a transcription factor; its target genes include Bcl-xL [160]. A Bcl-xL gene with a mutation in the STAT5 response element (STRE) failed to be activated by ginsenoside Rb1, whereas ginsenoside Rb1 treatment increased wild-type Bcl-xL activity by greater than 2 fold. In addition to prevention of cerebral ischemia, Bcl-xL-mediated neuroprotective effects of ginsenoside have been observed in spinal cord injury models [110,111,113] where red ginseng extract administration attenuated the expression of inflammatory cytokines, prevented morphological alteration of the spinal cord and improved rearing and locomotion activity. This group further showed that the neuroprotective properties of red ginseng extract are associated with its ability to upregulate protein levels of Bcl-xL and vascular endothelial growth factor (VEGF) [111,113]. Although the detailed mechanisms were not tested in these studies, VEGF has been reported to be a downstream target of Bcl-xL via the mitogen-activate protein kinase (MAPK) signaling pathway [161]; thus Bcl-xL may promote recovery after CNS injuries by supporting angiogenesis. In addition to transcriptional and translational regulation, ginsenosides may directly bind to Bcl-xL and control its activity. An in silico docking study predicted the interaction between Bcl-xL and ginsenosides, especially with Rg1, Rg2, Rg3, and Rd [162], and Ala142, Glu153, Thr109, Lys16, and Lys20 are reported as the predicted docking sites. In order to show biological significance of ginsenoside docking, verification of the interaction between Bcl-xL and ginsenosides using cells or in tissues will be required in future studies.

4. Omega-3 Fatty Acids
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are omega-3 (ω-3) fatty acids with 22-carbons and 20-carbons, respectively. Both fatty acids are found in fatty fish such as salmon, trout, and tuna. EPA and DHA are typically available in food or appropriate supplements, but they are also principle metabolites of the essential fatty acid α-linolenic acid. DHA and EPA are structural components of neuronal membranes, thus sufficient intake of omega-3 supports normal brain development [163,164], whereas deficiencies impair neuronal growth and plasticity [165,166,167].

Both in in vitro and in vivo models, application of omega-3 fatty acids has been noted to exert neuroprotection by enhancing the levels of Bcl-xL protein and modifying other Bcl-2 family protein levels [114,115,116,117,118,119,120,168,169]. Fat-1 gene encodes omega-3 fatty acid desaturase, the enzyme responsible for conversion of omega-6 fatty acids to omega-3 fatty acids. Tissues from Fat-1 mice are rich in omega-3 fatty acids such as EPA and DHA [170,171]. Shi et al. reported that cortical neurons isolated from Fat-1 mice were resistant to oxygen glucose deprivation (OGD)-mediated oxidative stress because Bcl-xL levels did not decline [118]. This group also showed that treatment with DHA (10 µM) significantly enhanced Bcl-xL protein in primary neuronal cultures indicating a regulatory effect of both endogenous and exogenous omega-3 fatty acids on Bcl-xL expression [118]. In addition, Fat-1 mice were protected from neuronal loss caused by infusion of amyloid beta (Aβ) 1-42, and primary cortical neurons isolated from Fat-1 embryos retained significantly higher levels of Bcl-xL protein under Aβ challenge [120]. 

Deficiency of thyroid hormone causes neuronal apoptosis associated with downregulation of Bcl-xL protein [116,172,173]. In a model of experimental hypothyroidism in pregnant rats, animals were protected from neuronal apoptosis by prior supplementation with 300 mg of omega-3 fatty acids [116]. Hypothyroid pups born from omega-3 fatty acid fed dams retained cerebellar weight and Bcl-xL protein in the cerebellum [116]. This group further showed that supplementation of omega-3 fatty acid inactivates c-Jun N-terminal kinase (JNK) and enhances phosphorylation of AKT and ERK [116]. AKT and ERK may enhance phosphorylation of pro-apoptotic Bcl-2 proteins [140,143] favoring survival by preventing dimerization of Bcl-xL. Interestingly, treatment with neuroprotectin D1, a derivative of omega-3 fatty acids, reverses phosphorylation of Bcl-xL by enhancing protein phosphatase 2A, an enzyme responsible for the dephosphorylation of Bcl-xL [174,175]. Therefore, omega-3 fatty acids may both decrease the functional population of pro-apoptotic Bcl-2 proteins and increase Bcl-xL in the brain favoring neuroprotection.

DHA treatment is reported to protect the brain in in vivo models of Parkinson’s disease [117]. Mice fed with DHA for 2 weeks were protected from dopaminergic cell loss induced by the dopaminergic toxin, 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) [117]. Supplementation of DHA significantly increased the mRNA expression of Bcl-xL, leading to the neuroprotective effect. This group also showed downregulation of phosphorylated JNK in the DHA fed group. Although both the JNK pathway and Bcl-xL are known to play a role in apoptosis, it is unclear if DHA independently controls JNK and Bcl-xL expression, or it intervenes with JNK-induced Bcl-xL regulation. Since phosphorylation is an important modification to change the function of Bcl-xL by blocking post-translational cleavage or interaction with pro-apoptotic proteins [103,176,177,178,179], alteration of upstream kinase activities by DHA may regulate apoptosis. 

Moreover, DHA application has been highly effective against oxidative stress-associated damage which is a common process during neurodegeneration [115,119]. Although mechanisms of DHA-mediated epigenetic control were not tested in these reports, DHA-induced augmentation of mRNA expression under oxidative stress is known to occur for the Bcl-xL gene, BCL2L1 in HT22 hippocampal cell line, without changes in Bcl-2 nor Bax gene expression [115]. Thus, DHA-dependent anti-apoptotic effect during oxidative stress may be primarily controlled by the Bcl-xL gene. Finally, treatment with DHA is reported to enhance neurite outgrowth in hippocampal neurons and to prevent loss of neurites during neurotoxicity [120,180]. Since Bcl-xL is required for neurite elongation and branching [21], DHA may be a potent candidate to promote rehabilitation or recovery of the brain after injury.

5. Resveratrol
Resveratrol, or 3,4,5-trihydroxystilbene, is part of a class of polyphenolic compounds called stilbenes. Resveratrol is in foods such as cocoa, various berries, and peanuts, but the most prominent sources in the human diet are grapes and grape products, such as wine. Although both red and white wines contain this compound, resveratrol content is markedly higher in red wines [181]. Resveratrol is notable for its role as a potent antioxidant by scavenging free radicals and increasing the activity of endogenous antioxidant enzymes, such as superoxide dismutase [182,183]. Additionally, it has been found to have additional benefits such as cardioprotection, anti-inflammatory, and anti-tumor properties [184,185,186,187]. 

Neuroprotective properties of resveratrol have been reported by various research groups. Administration of resveratrol attenuates brain damage caused by MCAO-induced ischemic stroke in rodents [188,189,190]. Resveratrol also exhibits protective effects in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease [191,192]. Resveratrol treatment regulated Bcl-xL and NF-κB protein levels in an in vitro Alzheimer’s disease model, and protected rat pheochromocytoma cells, PC12, against Aβ-induced oxidative stress [122]. Moreover, involvement of Bcl-xL in resveratrol-mediated neuroprotection in a cerebral ischemia model was reported [121]. Lanzillotta et al. exposed mouse primary cortical neurons to oxygen-glucose deprivation (OGD) for 3 h, and found that OGD decreased the activity of the Bcl-xL promoter. Interestingly, mutation of the nuclear factor-kappaB (NF-κB) binding site at the Bcl-xL promoter downregulated the basal activity of the Bcl-xL gene indicating NF-κB is an important transcriptional modulator of Bcl-xL gene expression [121]. RelA (also called p65), a subunit of NF-κB, is responsible for inducing Bcl-xL gene expression, but not that of Bcl-2 [193]. Lanzillotta’s group previously reported that acetylation of nuclear factor-kappaB (NF-κB) p50/RelA at Lys310 occurs during ischemia stroke, and deacetylation by a pharmacological inhibitor of acetylase and application of Lys310 mutation attenuates MCAO-induced neuronal injury [194]. Resveratrol activates sirtuin 1, an NAD-dependent deacetylase encoded by SIRT1 gene [195,196], thus resveratrol was applied to reverse acetylation of NF-κB RelA. Consistently, resveratrol enhanced Bcl-xL protein and protected SH-SY5Y cells from prion protein-induced cell death [123]. Seo et al. confirmed that resveratrol attenuates acetylation of p65, which enhances Bcl-xL promoter activity [193]. This group also showed that SH-SY5Y cells transduced with SIRT1 siRNA abolished resveratrol-mediated protection indicating that SIRT1 is the primary target of resveratrol in this model. These studies report that manipulating acetylation state using resveratrol supports recruitment of transcription factors at the Bcl-xL promoter enhancing the ratio of anti-apoptotic to pro-apoptotic gene products; this protects the brain against various apoptotic insults.

Although there are limited reports indicating a relationship between Bcl-xL and resveratrol in CNS disease models, numerous studies have reported that Bcl-2 and other members of Bcl-2 proteins are under the control of resveratrol [189,197,198,199,200,201]. Since apoptotic pathways are orchestrated by a series of highly coordinated actions of Bcl-xL and other Bcl-2 family proteins, it may be critical to dissect functions of Bcl-xL during resveratrol-mediated neuroprotection in future research. 

6. Alcohol
Alcohol, specifically ethanol, is a substance known to have varying effects on the brain. Although alcohol sensitivities may vary by dosage, time, cell type, and individual genetic differences [202], it is well-reported that aggressive alcohol usage leads to neurological damage, which is causative of behavioral and cognitive changes [203,204]. In contrast to its neurotoxic effects, moderate consumption of alcohol can be neuroprotective, lowering the risk of ischemic stroke and enhancing cognitive function in human subjects [205,206,207,208]. Similarly, treatment with ethanol during or after MCAO procedure improved energy metabolism and protected rodent brain from ischemic injury [209,210].

Despite limited information regarding the underlying mechanisms of alcohol-mediated neuroprotection, Bcl-2 proteins including Bcl-xL have been reported as important molecular targets [124,125,211,212]. Fu et al. showed upregulation of Bcl-xL protein in ethanol treated animals in an ischemic stroke model [124]. Rats undergoing MCAO-induced transient ischemia followed by reperfusion, had significantly decreased pro-apoptotic protein levels such as Bax, caspase 3, and apoptosis inducing factor (AIF) after administration of 1.5 g/kg ethanol, and the ethanol treatment enhanced anti-apoptotic Bcl-xL and Bcl-2 protein levels. Bcl-xL directly binds to Bax to inhibit Bax-mediated membrane permeabilization [213] and interaction between Bcl-xL and Bax prevents AIF release. Sequestration of pro-apoptotic Bax by Bcl-xL also prevents formation of the apoptosome blocking activation of caspase 3. Since caspase 3 is a key contributor in the conversion of anti-apoptotic Bcl-xL to pro-apoptotic fragmented ∆N-Bcl-xL during cerebral stroke [18,65,68], the ability of ethanol to prevent caspase 3 induction and to increase Bcl-xL protein levels directly prevents activation of apoptotic pathways. The same research team has reported that intraperitoneal injection of ethanol (1 g/kg) with normobaric oxygen therapy significantly increased Bcl-xL protein levels and attenuated stroke-induced neurological deficits [125]. However, it is well studied that alcohol consumption can also lead to apoptotic death via decreases in levels of Bcl-2 proteins in the brain [214,215,216]. Ethanol-induced Bcl-xL mRNA expression in brain cells is highly dependent on its concentration [124] and on the length of time of miRNA expression [217], thus determination of the therapeutic window of protection after ethanol treatment will be needed in future projects.

7. Conclusions
In this review, we have discussed food sources, nutrients, and phytochemicals that exert neuroprotection by regulating Bcl-xL (Table 2). Unlike surgical procedures or pharmacological approaches, nutritional therapy may not directly cure CNS disease or immediately relieve symptoms. However, nutritional intervention may delay propagation of neurotoxic signaling in the brain, facilitate recovery of damaged neurons, or support medical treatment by controlling an important molecular target that is essential for mitochondrial energy production, synaptic transmission, neurite outgrowth, and neuronal survival. Here, we suggest that nutrients are participants in molecular events and pathways, and are capable of regulating the protein target Bcl-xL and directly or indirectly other Bcl-2 family members via controlling transcription, translation, post-translational modification, and direct binding. Nutrients with regulatory potential may act synergistically with existing medications to reduce the risk of CNS disease.

Author Contributions
Writing-review & editing: H.-A.P.; K.B.; A.S.; S.K.; E.A.J.

Funding
This research was funded by Summer Research Support by the College of Human Environmental Sciences, the University of Alabama.

Conflicts of Interest
The authors declare no conflict of interest.

Figure 1 Conversion of Bcl-xL to ∆N-Bcl-xL. During neurotoxic stimulation (e.g., cerebral ischemia), full length Bcl-xL undergoes caspase-dependent N-terminus cleavage to pro-apoptotic ∆N-Bcl-xL.

molecules-23-03019-t001_Table 1Table 1 Neuroprotective properties of Bcl-xL in CNS-associated disease models.

CNS-Associated Disorders	References	
Ischemic stroke	[18,30,31,32,33,34,35]	
Spinal cord injury	[36,37,38,39,40]	
Alzheimer	[41,42,43,44]	
Parkinson	[45,46,47,48,49,50]	
Anxiety and Depression	[51,52,53]	
Traumatic Brain injury	[54,55,56]	
Spinal Muscular Dystrophy	[57,58,59,60,61]	
Schizophrenia	[62,63,64]	
molecules-23-03019-t002_Table 2Table 2 A list of dietary compounds that regulate Bcl-xL in the brain.

Nutrients and Foods	Roles	References	
High soy diet	Upregulation of Bcl-xL mRNA and protein in rats	[106]	
High soy diet	Upregulation of Bcl-xL mRNA and protein in rats MCAO model	[107]	
Orally gavaged soy isoflavones	Upregulation of Bcl-xL protein against Aβ-induced neurotoxicity in rats	[108]	
Intravenous infusion of ginsenoside	STAT5-dependent upregulation of Bcl-xL protein in rodent ischemia models (rats and gerbils) and primary cortical neurons	[109]	
Intravenous infusion of dihydroginsenoside Rb1	Upregulation of Bcl-xL mRNA in spinal cord injury and cerebral ischemia models	[110]	
Oral administration of red ginseng extract	Upregulation of Bcl-xL protein in rat spinal cord injury model	[111]	
Oral administration and intravenous infusion of ginsenoside 	Upregulation of Bcl-xL protein in mice during pneumococcal infection	[112]	
Intravenous infusion of ginsenoside	Upregulation of Bcl-xL protein in rat spinal cord injury model	[113]	
DHA or neuroprotectin D1 treatment in vitro	Upregulation of Bcl-xL gene in HN cell line	[114]	
DHA treatment in vitro	Upregulation of Bcl-xL mRNA in HT22 cell line against MNNG-induced toxicity	[115]	
Oral supplementation of DHA and EPA	Upregulation of Bcl-xL protein in hypothyroid rats	[116]	
Oral supplementation of DHA	Upregulation of Bcl-xL mRNA in mice brains after challenge with dopaminergic toxin	[117]	
Application with Fat-1 mouse model	Cortical neurons isolated from Fat-1 mice, genetically modified model with high endogenous omega-3 fatty acid levels, retained Bcl-xL protein against OGD	[118]	
DHA treatment in vitro	Upregulation of Bcl-xL protein in primary cortical neurons against oxyhemoglobin treatment	[119]	
Primary cortical neurons isolated from Fat-1 mice	Upregulation of Bcl-xL protein in primary cortical neurons against Aβ 1-42 treatment	[120]	
Intraperitoneal delivery of resveratrol 	Upregulation of acetylation of H3 histones on Bcl-xL promoter in mice	[121]	
Resveratrol treatment in vitro	Upregulation of Bcl-xL protein in PC12 cells	[122]	
Resveratrol treatment in vitro	Upregulation of Bcl-xL protein in SH-SY5Y cells	[123]	
Intraperitoneal injection of ethanol 	Upregulation of Bcl-xL protein in rat MCAO model	[124]	
Intraperitoneal injection of ethanol	Upregulation of Bcl-xL protein in rat MCAO model	[125]	
α-Tocopherol treatment in vitro	Downregulation of Bax/Bcl-xL protein ratio in PC 12 cells 	[126]	
Methyl donor deficient diet (no folate or vitamin B12)	Downregulation of Bcl-xL protein via miR-124-mediated Stat3 inhibition	[127]
==== Refs
References
1. Barclay L.A.  Wales T.E.  Garner T.P.  Wachter F.  Lee S.  Guerra R.M.  Stewart M.L.  Braun C.R.  Bird G.H.  Gavathiotis E.    Inhibition of pro-apoptotic bax by a noncanonical interaction mechanism Mol. Cell 2015 57 873 886 10.1016/j.molcel.2015.01.014 25684204 
2. Huang D.C.S.   The conserved N -terminal bh4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with ced-4 EMBO J. 1998 17 1029 1039 10.1093/emboj/17.4.1029 9463381 
3. Monaco G.  La Rovere R.  Karamanou S.  Welkenhuyzen K.  Ivanova H.  Vandermarliere E.  Di Martile M.  Del Bufalo D.  De Smedt H.  Parys J.B.    A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function FEBS J. 2018 285 127 145 10.1111/febs.14324 29131545 
4. Rong Y.-P.  Bultynck G.  Aromolaran A.S.  Zhong F.  Parys J.B.  De Smedt H.  Mignery G.A.  Roderick H.L.  Bootman M.D.  Distelhorst C.W.   The bh4 domain of Bcl-2 inhibits er calcium release and apoptosis by binding the regulatory and coupling domain of the ip3 receptor Proc. Nat. Acad. Sci. USA 2009 106 14397 14402 10.1073/pnas.0907555106 19706527 
5. Westphal D.  Kluck R.M.  Dewson G.   Building blocks of the apoptotic pore: How bax and bak are activated and oligomerize during apoptosis Cell Death Differ. 2013 21 196 205 10.1038/cdd.2013.139 24162660 
6. Desagher S.  Osen-Sand A.  Nichols A.  Eskes R.  Montessuit S.  Lauper S.  Maundrell K.  Antonsson B.  Martinou J.-C.   Bid-induced conformational change of bax is responsible for mitochondrial cytochrome c release during apoptosis J. Cell Biol. 1999 144 891 901 10.1083/jcb.144.5.891 10085289 
7. Wei M.C.  Lindsten T.  Mootha V.K.  Weiler S.  Gross A.  Ashiya M.  Thompson C.B.  Korsmeyer S.J.   tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c Gene. Dev. 2000 14 2060 2071 10950869 
8. Wei M.C.   Proapoptotic bax and bak: A requisite gateway to mitochondrial dysfunction and death Science 2001 292 727 730 10.1126/science.1059108 11326099 
9. Certo M.  Moore V.D.G.  Nishino M.  Wei G.  Korsmeyer S.  Armstrong S.A.  Letai A.   Mitochondria primed by death signals determine cellular addiction to antiapoptotic Bcl-2 family members Cancer Cell 2006 9 351 365 10.1016/j.ccr.2006.03.027 16697956 
10. Sattler M.   Structure of Bcl-xl-bak peptide complex: Recognition between regulators of apoptosis Science 1997 275 983 986 10.1126/science.275.5302.983 9020082 
11. Jurgensmeier J.M.  Xie Z.  Deveraux Q.  Ellerby L.  Bredesen D.  Reed J.C.   Bax directly induces release of cytochrome c from isolated mitochondria Proc. Natl. Acad. Sci. USA 1998 95 4997 5002 10.1073/pnas.95.9.4997 9560217 
12. Petros A.M.  Nettesheim D.G.  Wang Y.  Olejniczak E.T.  Meadows R.P.  Mack J.  Swift K.  Matayoshi E.D.  Zhang H.  Fesik S.W.    Rationale for Bcl-xl/bad peptide complex formation from structure, mutagenesis, and biophysical studies Protein Sci. 2000 9 2528 2534 10.1110/ps.9.12.2528 11206074 
13. Yang E.  Zha J.  Jockel J.  Boise L.H.  Thompson C.B.  Korsmeyer S.J.   Bad, a heterodimeric partner for Bcl-xl and Bcl-2, displaces bax and promotes cell death Cell 1995 80 285 291 10.1016/0092-8674(95)90411-5 7834748 
14. Chen Y.B.  Aon M.A.  Hsu Y.T.  Soane L.  Teng X.  McCaffery J.M.  Cheng W.-C.  Qi B.  Li H.  Alavian K.N.    Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential J. Cell Biol. 2011 195 263 276 10.1083/jcb.201108059 21987637 
15. Bertini I.  Chevance S.  Del Conte R.  Lalli D.  Turano P.   The anti-apoptotic Bcl-x(L.) protein, a new piece in the puzzle of cytochrome c interactome PLoS ONE 2011 6 e18329 10.1371/journal.pone.0018329 21533126 
16. Kharbanda S.  Pandey P.  Schofield L.  Israels S.  Roncinske R.  Yoshida K.  Bharti A.  Yuan Z.-M.  Saxena S.  Weichselbaum R.    Role for Bcl-xl as an inhibitor of cytosolic cytochrome c accumulation in dna damage-induced apoptosis Proc. Natl. Acad. Sci. USA 1997 94 6939 6942 10.1073/pnas.94.13.6939 9192670 
17. Nakamura A.  Swahari V.  Plestant C.  Smith I.  McCoy E.  Smith S.  Moy S.S.  Anton E.S.  Deshmukh M.   Bcl-xl is essential for the survival and function of differentiated neurons in the cortex that control complex behaviors J. Neurosci. 2016 36 5448 5461 10.1523/JNEUROSCI.4247-15.2016 27194326 
18. Ofengeim D.  Chen Y.  Miyawaki T.  Li H.  Sacchetti S.  Flannery R.J.  Alavian K.N.  Pontarelli F.  Roelofs B.A.  Hickman J.A.    N -terminally cleaved Bcl-xl mediates ischemia-induced neuronal death Nat. Neurosci. 2012 15 574 580 10.1038/nn.3054 22366758 
19. Naumenko V.S.  Kulikov A.V.  Kondaurova E.M.  Tsybko A.S.  Kulikova E.A.  Krasnov I.B.  Shenkman B.S.  Sychev V.N.  Bazhenova E.Y.  Sinyakova N.A.    Effect of actual long-term spaceflight on bdnf, trkb, p75, bax and Bcl-xl genes expression in mouse brain regions Neuroscience 2015 284 730 736 10.1016/j.neuroscience.2014.10.045 25451288 
20. Yoshida Y.  Liu J.Q.  Nakano Y.  Ueno S.  Ohmori S.  Fueta Y.  Ishidao T.  Kunugita N.  Yamashita U.  Hori H.   1-bp inhibits nf-κb activity and Bcl-xl expression in astrocytes in vitro and reduces Bcl-xl expression in the brains of rats in vivo NeuroToxicology 2007 28 381 386 10.1016/j.neuro.2006.05.015 16815550 
21. Park H.-A.  Licznerski P.  Alavian K.N.  Shanabrough M.  Jonas E.A.   Bcl-xl is necessary for neurite outgrowth in hippocampal neurons Antioxid. Redox 2015 22 93 108 10.1089/ars.2013.5570 24787232 
22. Lee J.  Kannagi M.  Ferrante R.J.  Kowall N.W.  Ryu H.   Activation of ets-2 by oxidative stress induces Bcl-xl expression and accounts for glial survival in amyotrophic lateral sclerosis FASEB J. 2009 23 1739 1749 10.1096/fj.08-121046 19179380 
23. Krajewska M.  Mai J.K.  Zapata J.M.  Ashwell K.W.  Schendel S.L.  Reed J.C.  Krajewski S.   Dynamics of expression of apoptosis-regulatory proteins bid, Bcl-2, Bcl-x, bax and bak during development of murine nervous system Cell Death Differ. 2002 9 145 157 10.1038/sj.cdd.4400934 11840165 
24. Alavian K.N.  Li H.  Collis L.  Bonanni L.  Zeng L.  Sacchetti S.  Lazrove E.  Nabili P.  Flaherty B.  Graham M.    Bcl-xl regulates metabolic efficiency of neurons through interaction with the mitochondrial f1 fo  atp synthase Nat. Cell Biol. 2011 13 1224 1233 10.1038/ncb2330 21926988 
25. Li H.  Alavian K.N.  Lazrove E.  Mehta N.  Jones A.  Zhang P.  Licznerski P.  Graham M.  Uo T.  Guo J.    A Bcl-xl–drp1 complex regulates synaptic vesicle membrane dynamics during endocytosis Nat. Cell Biol. 2013 15 773 785 10.1038/ncb2791 23792689 
26. Li H.  Chen Y.  Jones A.F.  Sanger R.H.  Collis L.P.  Flannery R.  McNay E.C.  Yu T.  Schwarzenbacher R.  Bossy B.    Bcl-xl induces drp1-dependent synapse formation in cultured hippocampal neurons Proc. Natl. Acad. Sci. USA 2008 105 2169 2174 10.1073/pnas.0711647105 18250306 
27. Jonas E.   BCL-xL regulates synaptic plasticity Mol. Interv. 2006 6 208 222 10.1124/mi.6.4.7 16960143 
28. Jonas E.  Porter G.A.  Beutner G.  Mnatsakanyan N.  Park H.A.  Mehta N.  Chen R.  Alavian K.N.   The mitochondrial permeability transition pore: Molecular structure and function in health and disease Molecular Basis for Mitochondrial Signaling Rostovtseva T.K.   Springer New York, NY, USA 2017 69 105 
29. Park H.A.  Jonas E.   Mitochondrial regulators of synaptic plasticity in the ischemic brain Synaptic Plasticity Heinbockel T.   INTECH London, UK 2017 39 67 
30. Cao G.  Pei W.  Ge H.  Liang Q.  Luo Y.  Sharp F.R.  Lu A.  Ran R.   In vivo delivery of a Bcl-xl fusion protein containing the tat protein transduction domain protects against ischemic brain injury and neuronal apoptosis J. Neurosci. 2002 22 5423 5431 10.1523/JNEUROSCI.22-13-05423.2002 12097494 
31. Wu C.  Fujihara H.  Yao J.  Qi S.  Li H.  Shimoji K.   Different expression patterns of Bcl-2, Bcl-xl, and Bax proteins after sublethal forebrain ischemia in C57Black/Crj6 mouse striatum Stroke A J. Cerebr. Circ. 2003 34 1803 1808 10.1161/01.STR.0000077255.15597.69 12791942 
32. Shimizu S.  Eguchi Y.  Kosaka H.  Kamiike W.  Matsuda H.  Tsujimoto Y.   Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xl Nature 1995 374 811 813 10.1038/374811a0 7723826 
33. Chen J.  Graham S.H.  Nakayama M.  Zhu R.L.  Jin K.  Stetler R.A.  Simon R.P.   Apoptosis repressor genes Bcl-2 and Bcl-x-long are expressed in the rat brain following global ischemia J. Cereb. Blood Flow Metab. 1997 2 10 10.1097/00004647-199701000-00002 8978381 
34. Wiessner C.  Allegrini P.R.  Rupalla K.  Sauer D.  Oltersdorf T.  McGregor A.L.  Bischoff S.  Böttiger B.W.  van der Putten H.   Neuron-specific transgene expression of Bcl-xl but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice Neurosci. Lett. 1999 268 119 122 10.1016/S0304-3940(99)00392-4 10406019 
35. Kilic E.  Dietz G.P.  Hermann D.M.  Bahr M.   Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice Ann Neurol. 2002 52 617 622 10.1002/ana.10356 12402259 
36. Qiu J.  Nesic O.  Ye Z.  Rea H.  Westlund K.N.  Xu G.Y.  McAdoo D.  Hulsebosch C.E.  Perez-Polo J.R.   Bcl-xL expression after contusion to the rat spinal cord J. Neurotrauma 2001 18 1267 1278 10.1089/089771501317095304 11721745 
37. Nesic-Taylor O.  Cittelly D.  Ye Z.  Xu G.Y.  Unabia G.  Lee J.C.  Svrakic N.M.  Liu X.H.  Youle R.J.  Wood T.G.    Exogenous Bcl-xl fusion protein spares neurons after spinal cord injury J. Neurosci. Res. 2005 79 628 637 10.1002/jnr.20400 15668909 
38. Lee S.I.  Kim B.G.  Hwang D.H.  Kim H.M.  Kim S.U.   Overexpression of Bcl-xlin human neural stem cells promotes graft survival and functional recovery following transplantation in spinal cord injury J. Neurosci. Res. 2009 87 3186 3197 10.1002/jnr.22149 19530162 
39. Zhou Z.  Peng X.  Insolera R.  Fink D.J.  Mata M.   IL-10 promotes neuronal survival following spinal cord injury Exp Neurol. 2009 220 183 190 10.1016/j.expneurol.2009.08.018 19716366 
40. Kadota R.  Koda M.  Kawabe J.  Hashimoto M.  Nishio Y.  Mannoji C.  Miyashita T.  Furuya T.  Okawa A.  Takahashi K.    Granulocyte colony-stimulating factor (g-csf) protects oligpdendrocyte and promotes hindlimb functional recovery after spinal cord injury in rats PLoS ONE 2012 7 e50391 10.1371/journal.pone.0050391 23209732 
41. Pike C.J.   Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: Relevance to Alzheimer’s disease J. Neurochem. 1999 72 1552 1563 10.1046/j.1471-4159.1999.721552.x 10098861 
42. Keil U.  Bonert A.  Marques C.A.  Scherping I.  Weyermann J.  Strosznajder J.B.  Müller-Spahn F.  Haass C.  Czech C.  Pradier L.    Amyloid β-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis J. Biol. Chem. 2004 279 50310 50320 10.1074/jbc.M405600200 15371443 
43. Hauptmann S.  Scherping I.  Dröse S.  Brandt U.  Schulz K.L.  Jendrach M.  Leuner K.  Eckert A.  Müller W.E.   Mitochondrial dysfunction: An early event in alzheimer pathology accumulates with age in ad transgenic mice Neurobiol. Aging 2009 30 1574 1586 10.1016/j.neurobiolaging.2007.12.005 18295378 
44. Vohra B.P.S.  Sasaki Y.  Miller B.R.  Chang J.  DiAntonio A.  Milbrandt J.   Amyloid precursor protein cleavage-dependent and -independent axonal degeneration programs share a common nicotinamide mononucleotide adenylyltransferase 1-sensitive pathway J. Neurosci. 2010 30 13729 13738 10.1523/JNEUROSCI.2939-10.2010 20943913 
45. Hartmann A.  Mouatt-Prigent A.  Vila M.  Abbas N.  Perier C.  Faucheux B.A.  Vyas S.  Hirsch E.C.   Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson’s disease Neurobiol. Dis. 2002 10 28 32 10.1006/nbdi.2002.0494 12079401 
46. Liste I.   The generation of dopaminergic neurons by human neural stem cells is enhanced by Bcl-xl, both in vitro and in vivo J. Neurosci. 2004 24 10786 10795 10.1523/JNEUROSCI.3208-04.2004 15574729 
47. Shim J.-W.   Enhanced in vitro midbrain dopamine neuron differentiation, dopaminergic function, neurite outgrowth, and 1-methyl-4-phenylpyridium resistance in mouse embryonic stem cells overexpressing Bcl-xl J. Neurosci. 2004 24 843 852 10.1523/JNEUROSCI.3977-03.2004 14749429 
48. Krabbe C.  Courtois E.  Jensen P.  Jørgensen J.R.  Zimmer J.  Martínez-Serrano A.  Meyer M.   Enhanced dopaminergic differentiation of human neural stem cells by synergistic effect of Bcl-xland reduced oxygen tension J. Neurochem. 2009 110 1908 1920 10.1111/j.1471-4159.2009.06281.x 19627448 
49. Courtois E.T.  Castillo C.G.  Seiz E.G.  Ramos M.  Bueno C.  Liste I.  Martinez-Serrano A.   In vitro and in vivo enhanced generation of human a9 dopamine neurons from neural stem cells by Bcl-xl J. Biol. Chem. 2010 285 9881 9897 10.1074/jbc.M109.054312 20106970 
50. Ren H.  Fu K.  Wang D.  Mu C.  Wang G.   Oxidized dj-1 interacts with the mitochondrial protein Bcl-xl J. Biol. Chem. 2011 286 35308 35317 10.1074/jbc.M110.207134 21852238 
51. Chiou S.H.  Ku H.H.  Tsai T.H.  Lin H.L.  Chen L.H.  Chien C.S.  Ho L.L.-T.  Lee C.-H.  Chang Y.-L.   Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway Br. J. Pharmacol. 2006 148 587 598 10.1038/sj.bjp.0706766 16702990 
52. Kosten T.A.  Galloway M.P.  Duman R.S.  Russell D.S.  D’Sa C.   Repeated unpredictable stress and antidepressants differentially regulate expression of the Bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures Neuropsychopharmacology 2007 33 1545 1558 10.1038/sj.npp.1301527 17700647 
53. Shishkina G.T.  Kalinina T.S.  Berezova I.V.  Dygalo N.N.   Stress-induced activation of the brainstem Bcl-xl gene expression in rats treated with fluoxetine: Correlations with serotonin metabolism and depressive-like behavior Neuropharmacology 2012 62 177 183 10.1016/j.neuropharm.2011.06.016 21740920 
54. Zhao J.  Li G.  Zhang Y.  Su X.  Hang C.   The potential role of jak2/stat3 pathway on the anti-apoptotic effect of recombinant human erythropoietin (rhepo) after experimental traumatic brain injury of rats Cytokine 2011 56 343 350 10.1016/j.cyto.2011.07.018 21843949 
55. Lončarević-Vasiljković N.  Milanović D.  Pešić V.  Tešić V.  Brkić M.  Lazić D.  Avramović V.  Kanazir S.   Dietary restriction suppresses apoptotic cell death, promotes Bcl-2 and Bcl-xl mrna expression and increases the Bcl-2/bax protein ratio in the rat cortex after cortical injury Neurochem. Int. 2016 96 69 76 10.1016/j.neuint.2016.02.017 26939764 
56. Pang A.L.  Xiong L.L.  Xia Q.J.  Liu F.  Wang Y.C.  Liu F.  Zhang P.  Meng B.-L.  Tan S.  Wang T.-H.   Neural stem cell transplantation is associated with inhibition of apoptosis, Bcl-xL upregulation, and recovery of neurological function in a rat model of traumatic brain injury. Cell Transpl. 2017 26 1262 1275 10.1177/0963689717715168 28933221 
57. Soler-Botija C.  Ferrer I.  Alvarez J.L.  Baiget M.  Tizzano E.F.   Downregulation of Bcl-2 proteins in type i spinal muscular atrophy motor neurons during fetal development J. Neuropathol. Exp. Neurol. 2003 62 420 426 10.1093/jnen/62.4.420 12722834 
58. Tsai L.K.  Tsai M.S.  Ting C.H.  Li H.   Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice J. Mol. Med. 2008 86 1243 1254 10.1007/s00109-008-0388-1 18649067 
59. Tsai L.K.  Tsai M.S.  Ting C.H.  Wang S.H.  Li H.   Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy Neurobiol. Dis. 2008 31 361 367 10.1016/j.nbd.2008.05.014 18590823 
60. Garcera A.  Mincheva S.  Gou-Fabregas M.  Caraballo-Miralles V.  Lladó J.  Comella J.X.  Soler R.M.   A new model to study spinal muscular atrophy: Neurite degeneration and cell death is counteracted by Bcl-xl overexpression in motoneurons Neurobiol. Dis. 2011 42 415 426 10.1016/j.nbd.2011.02.003 21333739 
61. Anderton R.S.  Price L.L.  Turner B.J.  Meloni B.P.  Mitrpant C.  Mastaglia F.L.  Goh C.  Wilton S.D.  Boulos S.   Co-regulation of survival of motor neuron and Bcl-xl expression: Implications for neuroprotection in spinal muscular atrophy Neuroscience 2012 220 228 236 10.1016/j.neuroscience.2012.06.042 22732506 
62. Wang C.  Kaufmann J.A.  Sanchez-Ross M.G.  Johnson K.M.   Mechanisms of N -methyl-d -aspartate-induced apoptosis in phencyclidine-treated cultured forebrain neurons J. Pharmacol. Exp. Ther. 2000 294 287 295 10871324 
63. Wang C.  McInnis J.  Ross-Sanchez M.  Shinnick-Gallagher P.  Wiley J.  Johnson K.   Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: Implications for schizophrenia Neuroscience 2001 107 535 550 10.1016/S0306-4522(01)00384-0 11720778 
64. He J.  Xu H.  Yang Y.  Rajakumar D.  Li X.  Li X.-M.   The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-xl/Bax ratio in the posterior cingulate cortex in rats Behav. Brain Res. 2006 168 236 242 10.1016/j.bbr.2005.11.014 16360889 
65. Clem R.J.  Cheng E.H.-Y.  Karp C.L.  Kirsch D.G.  Ueno K.  Takahashi A.  Kastan M.B.  Griffin D.E.  Earnshaw W.C.  Veliuona M.A.    Modulation of cell death by Bcl-xl through caspase interaction Proc. Natl. Acad. Sci. USA 1998 95 554 559 10.1073/pnas.95.2.554 9435230 
66. Miyawaki T.  Mashiko T.  Ofengeim D.  Flannery R.J.  Noh K.-M.  Fujisawa S.  Bonanni L.  Bennett M.V.L.  Zukin R.S.  Jonas E.A.   Ischemic preconditioning blocks bad translocation, Bcl-xl cleavage, and large channel activity in mitochondria of postischemic hippocampal neurons Proc. Natl. Acad. Sci. USA 2008 105 4892 4897 10.1073/pnas.0800628105 18347331 
67. Tanaka H.  Yokota H.  Jover T.  Cappuccio I.  Calderone A.  Simionescu M.  Bennett M.V.  Zukin R.S.   Ischemic preconditioning: Neuronal survival in the face of caspase-3 activation J. Neurosci. 2004 24 2750 2759 10.1523/JNEUROSCI.5475-03.2004 15028768 
68. Tornero D.  Posadas I.  Ceña V.   Bcl-xl blocks a mitochondrial inner membrane channel and prevents ca2+ overload-mediated cell death PLoS ONE 2011 6 e20423 10.1371/journal.pone.0020423 21674052 
69. Park H.A.  Jonas E.A.   ΔN -Bcl-xL, a therapeutic target for neuroprotection Neural Regen Res. 2017 12 1791 1794 10.4103/1673-5374.219033 29239317 
70. Jonas E.A.  Hickman J.A.  Chachar M.  Polster B.M.  Brandt T.A.  Fannjiang Y.  Ivanovska I.  Basanez G.  Kinnally K.W.  Zimmerberg J.    Proapoptotic n-truncated Bcl-xl protein activates endogenous mitochondrial channels in living synaptic terminals Proc. Natl. Acad. Sci. USA 2004 101 13590 13595 10.1073/pnas.0401372101 15342906 
71. Alavian K.N.  Beutner G.  Lazrove E.  Sacchetti S.  Park H.-A.  Licznerski P.  Li H.  Nabili P.  Hockensmith K.  Graham M.    An uncoupling channel within the c-subunit ring of the f1fo atp synthase is the mitochondrial permeability transition pore Proc. Natl. Acad. Sci. USA 2014 111 10580 10585 10.1073/pnas.1401591111 24979777 
72. White C.  Li C.  Yang J.  Petrenko N.B.  Madesh M.  Thompson C.B.  Foskett J.K.   The endoplasmic reticulum gateway to apoptosis by Bcl-xl modulation of the insp3r Nat. Cell Biol. 2005 7 1021 1028 10.1038/ncb1302 16179951 
73. Li C.  Wang X.  Vais H.  Thompson C.B.  Foskett J.K.  White C.   Apoptosis regulation by Bcl-xl modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating Proc. Natl. Acad. Sci. USA 2007 104 12565 12570 10.1073/pnas.0702489104 17636122 
74. Denton R.M.   Regulation of mitochondrial dehydrogenases by calcium ions Biochim. Biophys. Acta 2009 1787 1309 1316 10.1016/j.bbabio.2009.01.005 19413950 
75. Lai J.C.K.  DiLorenzo J.C.  Sheu K.-F.R.   Pyruvate dehydrogenase complex is inhibited in calcium-loaded cerebrocortical mitochondria Neurochem. Res. 1988 13 1043 1048 10.1007/BF00973148 3237304 
76. Contreras L.  Satrustegui J.   Calcium signaling in brain mitochondria: Interplay of malate aspartate nadh shuttle and calcium uniporter/mitochondrial dehydrogenase pathways J. Biol. Chem. 2009 284 7091 7099 10.1074/jbc.M808066200 19129175 
77. Hubbard M.J.  McHugh N.J.   Mitochondrial ATP synthase F1-beta-subunit is a calcium-binding protein FEBS Lett. 1996 391 323 329 10.1016/0014-5793(96)00767-3 8764999 
78. Territo P.R.  Mootha V.K.  French S.A.  Balaban R.S.   Ca2+  activation of heart mitochondrial oxidative phosphorylation: Role of the F(0)/F(1)-ATPase Am. J. Physiol. Cell Physiol. 2000 278 C423 C435 10.1152/ajpcell.2000.278.2.C423 10666039 
79. Boerries M.  Most P.  Gledhill J.R.  Walker J.E.  Katus H.A.  Koch W.J.  Aebi U.  Schoenenberger C.-A.   Ca2+ -dependent interaction of s100a1 with f1-atpase leads to an increased atp content in cardiomyocytes Mol. Cell. Biol. 2007 27 4365 4373 10.1128/MCB.02045-06 17438143 
80. Giorgio V.  Burchell V.  Schiavone M.  Bassot C.  Minervini G.  Petronilli V.  Argenton F.  Forte M.  Tosatto S.  Lippe G.    Ca2+  binding to F-ATP synthase β subunit triggers the mitochondrial permeability transition EMBO Rep. 2017 18 1065 1076 10.15252/embr.201643354 28507163 
81. Bezprozvanny I.  Ehrlich B.E.   Atp modulates the function of inositol 1,4,5-trisphosphate-gated channels at two sites Neuron 1993 10 1175 1184 10.1016/0896-6273(93)90065-Y 7686381 
82. Wagner L.E.  Betzenhauser M.J.  Yule D.I.   Atp binding to a unique site in the type-1 s2- inositol 1,4,5-trisphosphate receptor defines susceptibility to phosphorylation by protein kinase a J. Biol. Chem. 2006 281 17410 17419 10.1074/jbc.M601340200 16621795 
83. Huang H.  Hu X.  Eno C.O.  Zhao G.  Li C.  White C.   An interaction between Bcl-xland the voltage-dependent anion channel (vdac) promotes mitochondrial Ca2+  uptake J. Biol. Chem. 2013 288 19870 19881 10.1074/jbc.M112.448290 23720737 
84. Shoshan-Barmatz V.  Krelin Y.  Shteinfer-Kuzmine A.   VDAC1 functions in Ca2+  homeostasis and cell life and death in health and disease Cell Calcium 2018 69 81 100 10.1016/j.ceca.2017.06.007 28712506 
85. Monaco G.  Decrock E.  Arbel N.  van Vliet A.R.  La Rovere R.M.  De Smedt H.  Parys J.B.  Agostinis P.  Leybaert L.  Shoshan-Barmatz V.    The bh4 domain of anti-apoptotic Bcl-xl, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (vdac1)-mediated transfer of pro-apoptotic ca2+signals to mitochondria J. Biol. Chem. 2015 290 9150 9161 10.1074/jbc.M114.622514 25681439 
86. Madesh M.  Hajnoczky G.   VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release J. Cell Biol. 2001 155 1003 1015 10.1083/jcb.200105057 11739410 
87. Lemasters J.J.  Holmuhamedov E.   Voltage-dependent anion channel (vdac) as mitochondrial governator—Thinking outside the box Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2006 1762 181 190 10.1016/j.bbadis.2005.10.006 16307870 
88. Arbel N.  Ben-Hail D.  Shoshan-Barmatz V.   Mediation of the antiapoptotic activity of Bcl-xl protein upon interaction with vdac1 protein J. Biol. Chem. 2012 287 23152 23161 10.1074/jbc.M112.345918 22589539 
89. Malia T.J.  Wagner G.   Nmr structural investigation of the mitochondrial outer membrane protein vdac and its interaction with antiapoptotic Bcl-xl† Biochemistry 2007 46 514 525 10.1021/bi061577h 17209561 
90. Vander Heiden M.G.   Bcl-xl promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane J. Biol. Chem. 2001 276 19414 19419 10.1074/jbc.M101590200 11259441 
91. Vander-Heiden M.G.  Chandel N.S.  Li X.X.  Schumacker P.T.  Colombini M.  Thompson C.B.   Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival Proc. Nat. Acad. Sci. USA 2000 97 4666 4671 10.1073/pnas.090082297 10781072 
92. Nishida Y.  Arakawa S.  Fujitani K.  Yamaguchi H.  Mizuta T.  Kanaseki T.  Komatsu M.  Otsu K.  Tsujimoto Y.  Shimizu S.   Discovery of atg5/atg7-independent alternative macroautophagy Nature 2009 461 654 658 10.1038/nature08455 19794493 
93. Kang R.  Zeh H.J.  Lotze M.T.  Tang D.   The Beclin 1 network regulates autophagy and apoptosis Cell Death Diff. 2011 18 571 580 10.1038/cdd.2010.191 21311563 
94. Sinha S.  Levine B.   The autophagy effector Beclin 1: A novel BH3-only protein Oncogene 2008 27 S137 S148 10.1038/onc.2009.51 19641499 
95. Oberstein A.  Jeffrey P.D.  Shi Y.   Crystal structure of the Bcl-xl-beclin 1 peptide complex: Beclin 1 is a novel bh3-only protein J. Biol. Chem. 2007 282 13123 13132 10.1074/jbc.M700492200 17337444 
96. Kim S.-Y.  Song X.  Zhang L.  Bartlett D.L.  Lee Y.J.   Role of Bcl-xl/beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death Biochem. Pharmacol. 2014 88 178 188 10.1016/j.bcp.2014.01.027 24486574 
97. Maiuri M.C.  Le Toumelin G.  Criollo A.  Rain J.-C.  Gautier F.  Juin P.  Tasdemir E.  Pierron G.  Troulinaki K.  Tavernarakis N.    Functional and physical interaction between Bcl-xl and a bh3-like domain in beclin-1 EMBO J. 2007 26 2527 2539 10.1038/sj.emboj.7601689 17446862 
98. Lazarou M.  Sliter D.A.  Kane L.A.  Sarraf S.A.  Wang C.  Burman J.L.  Sideris D.P.  Fogel A.I.  Youle R.J.   The ubiquitin kinase pink1 recruits autophagy receptors to induce mitophagy Nature 2015 524 309 314 10.1038/nature14893 26266977 
99. Ordureau A.  Sarraf S.A.  Duda D.M.  Heo J.-M.  Jedrychowski M.P.  Sviderskiy V.O.  Olszewski J.L.  Koerber J.T.  Xie T.  Beausoleil S.A.    Quantitative proteomics reveal a feedforward mechanism for mitochondrial parkin translocation and ubiquitin chain synthesis Mol. Cell 2014 56 360 375 10.1016/j.molcel.2014.09.007 25284222 
100. McWilliams T.G.  Muqit M.M.   PINK1 and parkin: Emerging themes in mitochondrial homeostasis Curr. Opin. Cell Biol. 2017 45 83 91 10.1016/j.ceb.2017.03.013 28437683 
101. Pickrell A.M.  Youle R.J.   The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease Neuron 2015 85 257 273 10.1016/j.neuron.2014.12.007 25611507 
102. Geisler S.  Holmström K.M.  Treis A.  Skujat D.  Weber S.S.  Fiesel F.C.  Kahle P.J.  Springer W.   The pink1/parkin-mediated mitophagy is compromised by pd-associated mutations Autophagy 2010 6 871 878 10.4161/auto.6.7.13286 20798600 
103. Arena G.  Gelmetti V.  Torosantucci L.  Vignone D.  Lamorte G.  De Rosa P.  Cilia E.  Jonas E.A.  Valente E.M.   Pink1 protects against cell death induced by mitochondrial depolarization, by phosphorylating Bcl-xl and impairing its pro-apoptotic cleavage Cell Death Differ. 2013 20 920 930 10.1038/cdd.2013.19 23519076 
104. Hickman J.A.  Hardwick J.M.  Kaczmarek L.K.  Jonas E.A.   Bcl-xl inhibitor abt-737 reveals a dual role for Bcl-xl in synaptic transmission J. Neurophysiol. 2008 99 1515 1522 10.1152/jn.00598.2007 18160428 
105. He L.  Perkins G.A.  Poblenz A.T.  Harris J.B.  Hung M.  Ellisman M.H.  Fox D.A.   Bcl-xl overexpression blocks bax-mediated mitochondrial contact site formation and apoptosis in rod photoreceptors of lead-exposed mice Proc. Nat. Acad. Sci. USA 2003 100 1022 1027 10.1073/pnas.0333594100 12540825 
106. Lovekamp-Swan T.  Glendenning M.L.  Schreihofer D.A.   A high soy diet enhances neurotropin receptor and Bcl-xl gene expression in the brains of ovariectomized female rats Brain Res. 2007 1159 54 66 10.1016/j.brainres.2007.05.026 17582385 
107. Lovekamp-Swan T.  Glendenning M.  Schreihofer D.A.   A high soy diet reduces programmed cell death and enhances Bcl-xl expression in experimental stroke Neuroscience 2007 148 644 652 10.1016/j.neuroscience.2007.06.046 17706879 
108. Feng J.-F.  He L.  Li D.  Yuan L.-H.  Yu H.-L.  Ma W.-W.  Yang Y.  Xi Y.-D.  Ding J.  Xiao Y.-X.    Antagonizing effects of soybean isoflavones on β-amyloid peptides- induced oxidative damage in neuron mitochondria of rats Basic Clin. Pharmacol. Toxicol. 2012 10.1111/j.1742-7843.2012.00900.x 22551092 
109. Zhang B.  Hata R.  Zhu P.  Sato K.  Wen T.-C.  Yang L.  Fujita H.  Mitsuda N.  Tanaka J.  Samukawa K.    Prevention of ischemic neuronal death by intravenous infusion of a ginseng saponin, ginsenoside rb1, that upregulates Bcl-xl expression J. Cereb. Blood Flow Metab. 2006 26 708 721 10.1038/sj.jcbfm.9600225 16163298 
110. Sakanaka M.  Zhu P.  Zhang B.  Wen T.-C.  Cao F.  Ma Y.-J.  Samukawa K.  Mitsuda N.  Tanaka J.  Kuramoto M.    Intravenous infusion of dihydroginsenoside rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of vegf and Bcl-xL J. Neurotrauma 2007 24 1037 1054 10.1089/neu.2006.0182 17600519 
111. Zhu P.  Samukawa K.  Fujita H.  Kato H.  Sakanaka M.   Oral administration of red ginseng extract promotes neurorestoration after compressive spinal cord injury in rats Evid-Based Compl. Alt. Med. 2017 2017 1265464 10.1155/2017/1265464 28828029 
112. Lee S.  Lee S.O.  Kim G.L.  Rhee D.K.   Estrogen receptor-beta of microglia underlies sexual differentiation of neuronal protection via ginsenosides in mice brain CNS Neurosci. Ther. 2018 24 930 939 10.1111/cns.12842 29524300 
113. Zhu P.  Hata R.  Nakata K.  Cao F.  Samukawa K.  Fujita H.  Sakanaka M.   Intravenous infusion of ginsenoside Rb1 ameliorates compressive spinal cord injury through upregulation of Bcl-xL and VEGF Int. J. Neurol. Neurother. 2015 2 1 6 10.23937/2378-3001/2/1/1017 26658924 
114. Lukiw W.J.   A role for docosahexaenoic acid-derived neuroprotectin d1 in neural cell survival and alzheimer disease J. Clin. Investig. 2005 115 2774 2783 10.1172/JCI25420 16151530 
115. Cieslik M.  Pyszko J.  Strosznajder J.B.   Docosahexaenoic acid and tetracyclines as promising neuroprotective compounds with poly(adp-ribose) polymerase inhibitory activities for oxidative/genotoxic stress treatment Neurochem. Int. 2013 62 626 636 10.1016/j.neuint.2013.02.016 23439385 
116. Sinha R.A.  Khare P.  Rai A.  Maurya S.K.  Pathak A.  Mohan V.  Nagar G.K.  Mudiam M.K.R.  Godbole M.M.  Bandyopadhyay S.   Anti-apoptotic role of omega-3-fatty acids in developing brain: Perinatal hypothyroid rat cerebellum as apoptotic model Int. J. Dev. Neurosci. 2009 27 377 383 10.1016/j.ijdevneu.2009.02.003 19460632 
117. Wang C.  Wang D.  Xu J.  Yanagita T.  Xue C.  Zhang T.  Wang W.   DHA enriched phospholipids with different polar groups (PC and PS) had different improvements on MPTP-induced mice with Parkinson’s disease J. Funct. Foods. 2018 45 414 426 10.1016/j.jff.2018.04.017 
118. Shi Z.  Ren H.  Luo C.  Yao X.  Li P.  He C.  Kang J.-X.  Wan J.-B.  Yuan T.-F.  Su H.   Enriched endogenous omega-3 polyunsaturated fatty acids protect cortical neurons from experimental ischemic injury Mol. Neurobiol. 2015 53 6482 6488 10.1007/s12035-015-9554-y 26611833 
119. Zhang T.  Wu P.  Zhang J.H.  Li Y.  Xu S.  Wang C.  Wang L.  Zhang G.  Dai J.  Zhu S.    Docosahexaenoic acid alleviates oxidative stress-based apoptosis via improving mitochondrial dynamics in early brain injury after subarachnoid hemorrhage Cell Mol. Neurobiol. 2018 38 1413 1423 10.1007/s10571-018-0608-3 30084007 
120. Tan Y.  Ren H.  Shi Z.  Yao X.  He C.  Kang J.-X.  Wan J.-B.  Li P.  Yuan T.-F.  Su H.   Endogenous docosahexaenoic acid (dha) prevents aβ1–42 oligomer-induced neuronal injury Mol. Neurobiol. 2015 53 3146 3153 10.1007/s12035-015-9224-0 26021747 
121. Lanzillotta A.  Pignataro G.  Branca C.  Cuomo O.  Sarnico I.  Benarese M.  Annunziato L.  Spano P.  Pizzi M.   Targeted acetylation of nf-kappab/rela and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window Neurobiol. Dis. 2013 49 177 189 10.1016/j.nbd.2012.08.018 22971966 
122. Jang J.H.  Surh Y.J.   Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death Free Radic. Biol. Med. 2003 34 1100 1110 10.1016/S0891-5849(03)00062-5 12684095 
123. Seo J.-S.  Moon M.-H.  Jeong J.-K.  Seol J.-W.  Lee Y.-J.  Park B.-H.  Park S.-Y.   Sirt1, a histone deacetylase, regulates prion protein-induced neuronal cell death Neurobiol. Aging 2012 33 1110 1120 10.1016/j.neurobiolaging.2010.09.019 21074897 
124. Fu P.  Peng C.  Ding J.Y.  Asmaro K.  Sullivan J.M.  Guthikonda M.  Ding Y.   Acute administration of ethanol reduces apoptosis following ischemic stroke in rats Neurosci. Res. 2013 76 93 97 10.1016/j.neures.2013.02.011 23511554 
125. Geng X.  Parmar S.  Li X.  Peng C.  Ji X.  Chakraborty T.  Li W.A.  Du H.  Tan X.  Ling F.    Reduced apoptosis by combining normobaric oxygenation with ethanol in transient ischemic stroke Brain Res. 2013 1531 17 24 10.1016/j.brainres.2013.07.051 23920008 
126. Vlasova Y.A.  Zakharova I.O.  Avrova N.F.   The effects of alpha-tocoferol and H2 O2  on the mitochondrial membrane potential and Bax/Bcl-xL ratio in PC12 cells Neurochem. J. 2016 10 318 322 10.1134/S1819712416040152 
127. Kerek R.  Geoffroy A.  Bison A.  Martin N.  Akchiche N.  Pourié G.  Helle D.  Guéant J.-L.  Bossenmeyer-Pourié C.  Daval J.-L.   Early methyl donor deficiency may induce persistent brain defects by reducing stat3 signaling targeted by mir-124 Cell Death Dis. 2013 4 e755 10.1038/cddis.2013.278 23928694 
128. Boue S.M.  Wiese T.E.  Nehls S.  Burow M.E.  Elliott S.  Carter-Wientjes C.H.  Shih B.Y.  McLachlan J.A.   Evaluation of the estrogenic effects of legume extracts containing phytoestrogens J. Agric. Food Chem. 2003 51 2193 2199 10.1021/jf021114s 12670155 
129. Heinonen S.-M.  Hoikkala A.  Wähälä K.  Adlercreutz H.   Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects J. Steroid Biochem. Mol. Biol. 2003 87 285 299 10.1016/j.jsbmb.2003.09.003 14698210 
130. Vincent A.  Fitzpatrick L.A.   Soy isoflavones: Are they useful in menopause? Mayo Clin. Proc. 2000 75 1174 1184 10.4065/75.11.1174 11075748 
131. Morito K.  Hirose T.  Kinjo J.  Hirakawa T.  Okawa M.  Nohara T.  Ogawa S.  Inoue S.  Muramatsu M.  Masamune Y.   Interaction of phytoestrogens with estrogen receptors α and β Biol. Pharm. Bull. 2001 24 351 356 10.1248/bpb.24.351 11305594 
132. Patisaul H.B.   Soy isoflavone supplements antagonize reproductive behavior and estrogen receptor and dependent gene expression in the brain Endocrinology 2001 142 2946 2952 10.1210/endo.142.7.8241 11416015 
133. Ma T.C.  Campana A.  Lange P.S.  Lee H.-H.  Banerjee K.  Bryson J.B.  Mahishi L.  Alam S.  Giger R.J.  Barnes S.    A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a camp-independent pathway J. Neurosci. 2010 30 739 748 10.1523/JNEUROSCI.5266-09.2010 20071539 
134. Schreihofer D.A.   High-soy diet decreases infarct size after permanent middle cerebral artery occlusion in female rats AJP Regul. Integr. Comp. Physiol. 2005 289 R103 R108 10.1152/ajpregu.00642.2004 15956759 
135. Liu L.X.  Chen W.F.  Xie J.X.  Wong M.S.   Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson’s disease Neurosci Res. 2008 60 156 161 10.1016/j.neures.2007.10.005 18054104 
136. Wang S.  Wei H.  Cai M.  Lu Y.  Hou W.  Yang Q.  Dong H.  Xiong L.   Genistein attenuates brain damage induced by transient cerebral ischemia through up-regulation of erk activity in ovariectomized mice Int. J. Boil. Sci. 2014 10 457 465 10.7150/ijbs.7562 24719563 
137. Jiang T.  Wang X.Q.  Ding C.  Du X.L.   Genistein attenuates isoflurane-induced neurotoxicity and improves impaired spatial learning and memory by regulating cAMP/CREB and BDNF-TrkB-PI3K/Akt signaling Korean J. Physiol. Pharmacol. 2017 21 579 589 10.4196/kjpp.2017.21.6.579 29200900 
138. Grillot D.A.  Gonzalez-Garcia M.  Ekhterae D.  Duan L.  Inohara N.  Ohta S.  Seldin M.F.  Nuñez G.   Genomic organization, promoter region analysis, and chromosome localization of the mouse Bcl-x gene J. Immunol. 1997 158 4750 4757 9144489 
139. Setchell K.D.  Brown N.M.  Zimmer-Nechemias L.  Brashear W.T.  Wolfe B.E.  Kirschner A.S.  Heubi J.E.   Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability Am. J. Clin. Nutr. 2002 76 447 453 10.1093/ajcn/76.2.447 12145021 
140. Datta S.R.  Dudek H.  Tao X.  Masters S.  Fu H.  Gotoh Y.  Greenberg M.E.   Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery Cell 1997 91 231 241 10.1016/S0092-8674(00)80405-5 9346240 
141. Gardai S.J.  Hildeman D.A.  Frankel S.K.  Whitlock B.B.  Frasch S.C.  Borregaard N.  Marrack P.  Bratton D.L.  Henson P.M.   Xphosphorylation of bax ser184 by akt regulates its activity and apoptosis in neutrophils J. Biol. Chem. 2004 279 21085 21095 10.1074/jbc.M400063200 14766748 
142. Koh P.-O.   Nicotinamide attenuates the ischemic brain injury-induced decrease of akt activation and bad phosphorylation Neurosci. Lett. 2011 498 105 109 10.1016/j.neulet.2011.05.003 21596097 
143. Tan Y.  Demeter M.R.  Ruan H.  Comb M.J.   Bad ser-155 phosphorylation regulates bad/Bcl-xl interaction and cell survival J. Biol. Chem. 2000 275 25865 25869 10.1074/jbc.M004199200 10837486 
144. Nunan J.  Small D.H.   Regulation of APP cleavage by α-, β- and γ-secretases FEBS Lett. 2000 483 6 10 10.1016/S0014-5793(00)02076-7 11033346 
145. Chow V.W.  Mattson M.P.  Wong P.C.  Gleichmann M.   An overview of APP processing enzymes and products Neuromol. Med. 2010 12 1 12 10.1007/s12017-009-8104-z 20232515 
146. Stone J.R.  Okonkwo D.O.  Singleton R.H.  Mutlu L.K.  Helm G.A.  Povlishock J.T.   Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid β peptide in traumatic axonal injury J. Neurotrauma 2002 19 601 614 10.1089/089771502753754073 12042095 
147. Lu D.C.  Soriano S.  Bredesen D.E.  Koo E.H.   Caspase cleavage of the amyloid precursor protein modulates amyloid β-protein toxicity J. Neurochem. 2003 87 733 741 10.1046/j.1471-4159.2003.02059.x 14535955 
148. Carthy C.M.  Yanagawa B.  Luo H.  Granville D.J.  Yang D.  Cheung P.  Cheung C.  Esfandiarei M.  Rudin C.M.  Thompson C.B.    Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection Virology 2003 313 147 157 10.1016/S0042-6822(03)00242-3 12951029 
149. Hu Y.  Benedict M.A.  Wu D.  Inohara N.  Nunez G.   Bcl-xl interacts with apaf-1 and inhibits apaf-1-dependent caspase-9 activation Proc. Nat. Acad. Sci. USA 1998 95 4386 4391 10.1073/pnas.95.8.4386 9539746 
150. Hou J.P.   The chemical constituents of ginseng plants Comp. Med. East West. 1977 5 123 145 10.1142/S0147291777000209 608333 
151. Lu J.M.  Yao Q.  Chen C.   Ginseng compounds: An update on their molecular mechanisms and medical applications Curr. Vasc. Pharmacol. 2009 7 293 302 10.2174/157016109788340767 19601854 
152. Hofseth L.J.  Wargovich M.J.   Inflammation, cancer, and targets of ginseng J Nutr. 2007 37 183S 185S 10.1093/jn/137.1.183S 17182823 
153. Kitts D.D.  Wijewickreme A.N.  Hu C.   Antioxidant properties of a North American ginseng extract Mol. Cell Biochem. 2000 203 1 10 10.1023/A:1007078414639 10724326 
154. Ahn J.-Y.  Choi I.-S.  Shim J.-Y.  Yun E.-K.  Yun Y.-S.  Jeong G.  Song J.-Y.   The immunomodulator ginsan induces resistance to experimental sepsis by inhibiting toll-like receptor-mediated inflammatory signals Eur. J. Immunol. 2006 36 37 45 10.1002/eji.200535138 16342327 
155. Keum Y.-S.  Han S.S.  Chun K.-S.  Park K.-K.  Park J.-H.  Lee S.K.  Surh Y.-J.   Inhibitory effects of the ginsenoside rg3 on phorbol ester-induced cyclooxygenase-2 expression, nf-κb activation and tumor promotion Mutat. Res. Mol. Mech. Mutagen. 2003 523–524 75 85 10.1016/S0027-5107(02)00323-8 
156. Xu K.  Zhang Y.  Wang Y.  Ling P.  Xie X.  Jiang C.  Zhang Z.  Lian X.-Y.   Ginseng rb fraction protects glia, neurons and cognitive function in a rat model of neurodegeneration PLoS ONE 2014 9 e101077 10.1371/journal.pone.0101077 24971630 
157. Lin M.  Sun W.  Gong W.  Ding Y.  Zhuang Y.  Hou Q.   Ginsenoside rg1 protects against transient focal cerebral ischemic injury and suppresses its systemic metabolic changes in cerabral injury rats Acta Pharm. Sin. B 2015 5 277 284 10.1016/j.apsb.2015.02.001 26579457 
158. Zhang C.  Li C.  Chen S.  Li Z.  Ma L.  Jia X.  Wang K.  Bao J.  Liang Y.  Chen M.W.    Hormetic effect of panaxatriol saponins confers neuroprotection in PC12 cells and zebrafish through PI3K/AKT/mTOR and AMPK/SIRT1/FOXO3 pathways Sci. Rep. 2017 7 41082 10.1038/srep41082 28112228 
159. Liu Y.  Zhang R.-Y.  Zhao J.  Dong Z.  Feng D.-Y.  Wu R.  Shi M.  Zhao G.   Ginsenoside rd protects sh-sy5y cells against 1-methyl-4-phenylpyridinium induced injury Int. J. Mol. Sci. 2015 16 14395 14408 10.3390/ijms160714395 26114390 
160. Al Zaid Siddiquee K.  Turkson J.   STAT3 as a target for inducing apoptosis in solid and hematological tumors Cell Res. 2008 18 254 267 10.1038/cr.2008.18 18227858 
161. Karl E.  Zhang Z.  Dong Z.  Neiva K.G.  Soengas M.S.  Koch A.E.  Polverini P.J.  Núñez G.  Nör J.E.   Unidirectional crosstalk between Bcl-xl and Bcl-2 enhances the angiogenic phenotype of endothelial cells Cell Death Differ. 2007 14 1657 1666 10.1038/sj.cdd.4402174 17572663 
162. Sathishkumar N.  Sathiyamoorthy S.  Ramya M.  Yang D.-U.  Lee H.N.  Yang D.-C.   Molecular docking studies of anti-apoptotic Bcl-2, Bcl-xl, and mcl-1 proteins with ginsenosides frompanax ginseng J. Enzym. Inhib. Med. Chem. 2011 27 685 692 10.3109/14756366.2011.608663 21919598 
163. Innis S.M.   Dietary (n -3) fatty acids and brain development J. Nutr. 2007 137 855 859 10.1093/jn/137.4.855 17374644 
164. Cao D.  Kevala K.  Kim J.  Moon H.S.  Jun S.B.  Lovinger D.  Kim H.-Y.   Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function J. Neurochem. 2009 111 510 521 10.1111/j.1471-4159.2009.06335.x 19682204 
165. Lukiw W.J.  Bazan N.G.   Docosahexaenoic acid and the aging brain J. Nutr. 2008 138 2510 2514 10.3945/jn.108.096016 19022980 
166. McNamara R.K.  Carlson S.E.   Role of omega-3 fatty acids in brain development and function: Potential implications for the pathogenesis and prevention of psychopathology Prostaglandins Leuk. Essent. Fat. Acids 2006 75 329 349 10.1016/j.plefa.2006.07.010 16949263 
167. Bhatia H.S.  Agrawal R.  Sharma S.  Huo Y.-X.  Ying Z.  Gomez-Pinilla F.   Omega-3 fatty acid deficiency during brain maturation reduces neuronal and behavioral plasticity in adulthood PLoS ONE 2011 6 e28451 10.1371/journal.pone.0028451 22163304 
168. Chang Y.-L.  Chen S.-J.  Kao C.-L.  Hung S.-C.  Ding D.-C.  Yu C.-C.  Chen Y.-J.  Ku H.-H.  Lin C.-P.  Lee K.-H.    Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with parkinson-like pathology Cell Transpl. 2012 21 313 332 10.3727/096368911X580572 21669041 
169. Zhang C.  Bazan N.G.   Lipid-mediated cell signaling protects against injury and neurodegeneration J Nutr. 2010 140 858 863 10.3945/jn.109.114884 20181788 
170. Kang J.X.  Wang J.  Wu L.  Kang Z.B.   Transgenic mice: Fat-1 mice convert n-6 to n-3 fatty acids Nature 2004 427 504 10.1038/427504a 14765186 
171. Kang J.X.   Fat-1 transgenic mice: A new model for omega-3 research Prostaglandins Leuk. Essent. Fat. Acids 2007 77 263 267 10.1016/j.plefa.2007.10.010 18042365 
172. Singh R.  Upadhyay G.  Kumar S.  Kapoor A.  Kumar A.  Tiwari M.  Godbole M.M.   Hypothyroidism alters the expression of Bcl-2 family genes to induce enhanced apoptosis in the developing cerebellum J. Endocrinol. 2003 176 39 46 10.1677/joe.0.1760039 12525248 
173. Kumar A.  Sinha R.A.  Tiwari M.  Pal L.  Shrivastava A.  Singh R.  Kumar K.  Kumar Gupta S.  Godbole M.M.   Increased pro-nerve growth factor and p75 neurotrophin receptor levels in developing hypothyroid rat cerebral cortex are associated with enhanced apoptosis Endocrinology 2006 147 4893 4903 10.1210/en.2006-0027 16794016 
174. Antony R.  Lukiw W.J.  Bazan N.G.   Neuroprotectin d1 induces dephosphorylation of Bcl-xl in a pp2a-dependent manner during oxidative stress and promotes retinal pigment epithelial cell survival J. Boil. Chem. 2010 285 18301 18308 10.1074/jbc.M109.095232 20363734 
175. Bazan N.G.   Neuroprotectin d1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and alzheimer’s disease J. Lipid Res. 2008 50 S400 S405 10.1194/jlr.R800068-JLR200 19018037 
176. Megyesi J.  Tarcsafalvi A.  Seng N.  Hodeify R.  Price P.   Cdk2 phosphorylation of Bcl-xl after stress converts it to a pro-apoptotic protein mimicking bax/bak Cell Death Discov. 2016 2 15066 10.1038/cddiscovery.2015.66 27226901 
177. Cittelly D.M.  Nesic-Taylor O.  Perez-Polo J.R.   Phosphorylation of Bcl-xL after spinal cord injury J. Neurosci. Res. 2007 85 1894 1911 10.1002/jnr.21313 17551978 
178. Veas-Perez de Tudela M.  Delgado-Esteban M.  Maestre C.  Bobo-Jimenez V.  Jimenez-Blasco D.  Vecino R.  Bolaños J.P.  Almeida A.   Regulation of Bcl-xL-ATP synthase interaction by mitochondrial cyclin b1-cyclin-dependent kinase-1 determines neuronal survival J. Neurosci. 2015 35 9287 9301 10.1523/JNEUROSCI.4712-14.2015 26109654 
179. Fan M.  Goodwin M.  Vu T.  Brantley-Finley C.  Gaarde W.A.  Chambers T.C.   Vinblastine-induced phosphorylation of Bcl-2 and Bcl-xl is mediated by jnk and occurs in parallel with inactivation of the raf-1/mek/erk cascade J. Biol. Chem. 2000 275 29980 29985 10.1074/jbc.M003776200 10913135 
180. Calderon F.  Kim H.Y.   Docosahexaenoic acid promotes neurite growth in hippocampal neurons J. Neurochem. 2004 90 979 988 10.1111/j.1471-4159.2004.02520.x 15287904 
181. Tosun İ.  İnkaya A.N.   Resveratrol as a health and disease benefit agent Food Rev. Int. 2010 26 85 101 10.1080/87559120802525459 
182. Khan M.A.  Chen H.  Wan X.  Tania M.  Xu A.  Chen F.  Zhang D.   Regulatory effects of resveratrol on antioxidant enzymes: A mechanism of growth inhibition and apoptosis induction in cancer cells Mol. Cells 2013 35 219 225 10.1007/s10059-013-2259-z 23456297 
183. Schmatz R.  Perreira L.B.  Stefanello N.  Mazzanti C.  Spanevello R.  Gutierres J.  Bagatini M.  Martins C.C.  Abdalla F.H.  da Silva Serres J.D.    Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats Biochimie 2012 94 374 383 10.1016/j.biochi.2011.08.005 21864646 
184. Kuršvietienė L.  Stanevičienė I.  Mongirdienė A.  Bernatonienė J.   Multiplicity of effects and health benefits of resveratrol Medicina 2016 52 148 155 10.1016/j.medici.2016.03.003 27496184 
185. Wu J.M.  Hsieh T.C.   Resveratrol: A cardioprotective substance Ann. N. Y. Acad Sci. 2011 1215 16 21 10.1111/j.1749-6632.2010.05854.x 21261637 
186. Carter L.G.  D’Orazio J.A.  Pearson K.J.   Resveratrol and cancer: Focus on in vivo evidence Endocr. Relat. Cancer 2014 21 R209 R225 10.1530/ERC-13-0171 24500760 
187. Das S.  Das D.K.   Anti-inflammatory responses of resveratrol Inflamm. Allergy Drug Targets 2007 6 168 173 10.2174/187152807781696464 17897053 
188. Shin J.A.  Lee K.-E.  Kim H.-S.  Park E.-M.   Acute Resveratrol treatment modulates multiple signaling pathways in the ischemic brain Neurochem. Res. 2012 37 2686 2696 10.1007/s11064-012-0858-2 22878646 
189. Li Z.  Pang L.  Fang F.  Zhang G.  Zhang J.  Xie M.  Wang L.   Resveratrol attenuates brain damage in a rat model of focal cerebral ischemia via up-regulation of hippocampal Bcl-2 Brain Res. 2012 1450 116 124 10.1016/j.brainres.2012.02.019 22410291 
190. Koronowski K.B.  Dave K.R.  Saul I.  Camarena V.  Thompson J.W.  Neumann J.T.  Young J.I.  Perez-Pinzon M.A.   Resveratrol preconditioning induces a novel extended window of ischemic tolerance in the mouse brain Stroke 2015 46 2293 2298 10.1161/STROKEAHA.115.009876 26159789 
191. Li F.  Gong Q.  Dong H.  Shi J.   Resveratrol, a neuroprotective supplement for Alzheimer’s disease Curr. Pharm. Des. 2012 18 27 33 10.2174/138161212798919075 22211686 
192. Ferretta A.  Gaballo A.  Tanzarella P.  Piccoli C.  Capitanio N.  Nico B.  Annese T.  Di Paola M.  Dell’Aquila C.  De Mari M.    Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson’s disease Biochim. Biophys. Acta 2014 1842 902 915 10.1016/j.bbadis.2014.02.010 24582596 
193. Chen C.  Edelstein L.C.  Gelinas C.   The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L) Mol. Cell Biol. 2000 20 2687 2695 10.1128/MCB.20.8.2687-2695.2000 10733571 
194. Lanzillotta A.  Sarnico I.  Ingrassia R.  Boroni F.  Branca C.  Benarese M.  Faraco G.  Blasi F.  Chiarugi A.  Spano P.    The acetylation of rela in lys310 dictates the nf-κb-dependent response in post-ischemic injury Cell Death Dis. 2010 1 e96 10.1038/cddis.2010.76 21368872 
195. Howitz K.T.  Bitterman K.J.  Cohen H.Y.  Lamming D.W.  Lavu S.  Wood J.G.  Zipkin R.E.  Chung P.  Kisielewski A.  Zhang L.-L.    Small molecule activators of sirtuins extend saccharomyces cerevisiae lifespan Nature 2003 425 191 196 10.1038/nature01960 12939617 
196. Gertz M.  Nguyen G.T.  Fischer F.  Suenkel B.  Schlicker C.  Franzel B.  Tomaschewski J.  Aladini F.  Becker C.  Wolters D.    A molecular mechanism for direct sirtuin activation by resveratrol PLoS ONE 2012 7 e49761 10.1371/journal.pone.0049761 23185430 
197. Fang L.  Gao H.  Zhang W.  Zhang W.  Wang Y.   Resveratrol alleviates nerve injury after cerebral ischemia and reperfusion in mice by inhibiting inflammation and apoptosis Int. J. Clin. Exp. Med. 2015 8 3219 3226 26064211 
198. Kizmazoglu C.  Aydin H.E.  Sevin I.E.  Kalemci O.  Yüceer N.  Atasoy M.A.   Neuroprotective effect of resveratrol on acute brain ischemia reperfusion injury by measuring annexin v, p53, Bcl-2 levels in rats J. Korean Neurosurg. Soc. 2015 58 508 512 10.3340/jkns.2015.58.6.508 26819684 
199. Wang H.  Yang Y.  Zhang H.  Yan H.  Wu X.  Zhang C.   Administration of the resveratrol analogues isorhapontigenin and heyneanol-a protects mice hematopoietic cells against irradiation injuries BioMed Res. Int. 2014 2014 1 9 10.1155/2014/282657 25050334 
200. Liu Y.  Yang H.  Jia G.  Li L.  Chen H.  Bi J.  Wang C.L.   The Synergistic Neuroprotective Effects of Combined Rosuvastatin and Resveratrol Pretreatment against Cerebral Ischemia/Reperfusion Injury J. Stroke Cerebrovasc. Dis. 2018 27 1697 1704 10.1016/j.jstrokecerebrovasdis.2018.01.033 29525080 
201. Agrawal M.  Kumar V.  Kashyap M.P.  Khanna V.K.  Randhawa G.S.  Pant A.B.   Ischemic insult induced apoptotic changes in pc12 cells: Protection by trans resveratrol Eur. J. Pharmacol. 2011 666 5 11 10.1016/j.ejphar.2011.05.015 21620820 
202. Kaplan J.S.  Mohr C.  Rossi D.J.   Opposite actions of alcohol on tonic gabaa receptor currents mediated by nnos and pkc activity Nat. Neurosci. 2013 16 1783 1793 10.1038/nn.3559 24162656 
203. Holmes A.  Fitzgerald P.J.  MacPherson K.P.  DeBrouse L.  Colacicco G.  Flynn S.M.  Masneuf S.  Pleil K.E.  Li C.  Marcinkiewcz C.A.    Chronic alcohol remodels prefrontal neurons and disrupts nmdar-mediated fear extinction encoding Nat. Neurosci. 2012 15 1359 1361 10.1038/nn.3204 22941108 
204. Taffe M.A.  Kotzebue R.W.  Crean R.D.  Crawford E.F.  Edwards S.  Mandyam C.D.   Long-lasting reduction in hippocampal neurogenesis by alcohol consumption in adolescent nonhuman primates Proc. Nat. Acad. Sci. USA 2010 107 11104 11109 10.1073/pnas.0912810107 20534463 
205. Stampfer M.J.  Kang J.H.  Chen J.  Cherry R.  Grodstein F.   Effects of moderate alcohol consumption on cognitive function in women N. Engl. J. Med. 2005 352 245 253 10.1056/NEJMoa041152 15659724 
206. Sacco R.L.  Elkind M.  Boden-Albala B.  Lin I.F.  Kargman D.E.  Hauser W.A.  Shea S.  Paik M.C.   The protective effect of moderate alcohol consumption on ischemic stroke JAMA 1999 281 53 60 10.1001/jama.281.1.53 9892451 
207. Ruitenberg A.  van Swieten J.C.  Witteman J.C.  Mehta K.M.  van Duijn C.M.  Hofman A.  Breteler M.M.B.   Alcohol consumption and risk of dementia: The rotterdam study Lancet 2002 359 281 286 10.1016/S0140-6736(02)07493-7 11830193 
208. Ronksley P.E.  Brien S.E.  Turner B.J.  Mukamal K.J.  Ghali W.A.   Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis BMJ 2011 342 d671 10.1136/bmj.d671 21343207 
209. Geng X.  Fu P.  Ji X.  Peng C.  Fredrickson V.  Sy C.  Meng R.  Ling F.  Du H.  Tan X.    Synergetic neuroprotection of normobaric oxygenation and ethanol in ischemic stroke through improved oxidative mechanism Stroke 2013 44 1418 1425 10.1161/STROKEAHA.111.000315 23512978 
210. Kochanski R.  Peng C.  Higashida T.  Geng X.  Hüttemann M.  Guthikonda M.  Ding Y.   Neuroprotection conferred by post-ischemia ethanol therapy in experimental stroke: An inhibitory effect on hyperglycolysis and nadph oxidase activation J. Neurochem. 2013 126 113 121 10.1111/jnc.12169 23350720 
211. Ye Y.  Li J.  Cao X.  Chen Y.  Ye C.  Chen K.   Protective effect of n -butyl alcohol extracts from Rhizoma Pinelliae Pedatisectae against cerebral ischemia-reperfusion injury in rats J. Ethnopharmacol. 2016 188 259 265 10.1016/j.jep.2016.04.046 27132713 
212. Yu S.-S.  Zhao J.  Zheng W.-P.  Zhao Y.   Neuroprotective effect of 4-hydroxybenzyl alcohol against transient focal cerebral ischemia via anti-apoptosis in rats Brain Res. 2010 1308 167 175 10.1016/j.brainres.2009.10.037 19857470 
213. Billen L.P.  Kokoski C.L.  Lovell J.F.  Leber B.  Andrews D.W.   Bcl-xl inhibits membrane permeabilization by competing with bax PLoS Biol. 2008 6 e147 10.1371/journal.pbio.0060147 18547146 
214. Siler-Marsiglio K.I.  Madorsky I.  Pan Q.  Paiva M.  Neeley A.W.  Shaw G.  Heaton M.B.   Effects of acute ethanol exposure on regulatory mechanisms of Bcl-2-associated apoptosis promoter, bad, in neonatal rat cerebellum: Differential effects during vulnerable and resistant developmental periods Alcohol. Clin. Exp. Res. 2006 30 1031 1038 10.1111/j.1530-0277.2006.000126.x 16737462 
215. Han J.Y.  Jeong E.Y.  Kim Y.S.  Roh G.S.  Kim H.J.  Kang S.S.  Cho G.J.  Choi W.S.   C-jun N -terminal kinase regulates the interaction between 14-3-3 and bad in ethanol-induced cell death J. Neurosci. Res. 2008 86 3221 3229 10.1002/jnr.21759 18521936 
216. Bazovkina D.V.  Tsybko A.S.  Filimonova E.A.  Ilchibaeva T.V.  Naumenko V.S.   Influence of chronic alcohol treatment on the expression of the bdnf, bax, Bcl-xl, and casp3 genes in the mouse brain: Role of the c1473g polymorphism in the gene encoding tryptophan hydroxylase 2 Mol. Biol. 2016 50 262 269 10.1134/S0026893316010027 
217. Lee J.-H.  Tajuddin N.F.  Druse M.J.   Effects of ethanol and ipsapirone on the expression of genes encoding anti-apoptotic proteins and an antioxidant enzyme in ethanol-treated neurons Brain Res. 2009 1249 54 60 10.1016/j.brainres.2008.10.013 18992726

